UNICYCIVE THERAPEUTICS, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $675.0K | $951.0K | — | — |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | $9.1M | $20.0M | $12.9M | $12.4M | $6.1M | $1.0M |
| SG&A Expense | — | $20.4M | $12.1M | $8.5M | $383.0K | $245.0K | $58.0K |
| Operating Income | — | $-29.5M | $-32.1M | $-20.8M | $-18.1M | $-9.0M | $-2.0M |
| Operating Margin | — | — | — | -3,077.6% | -1,898.2% | — | — |
| Interest Expense | — | — | — | $82.0K | $6.0K | $628.0K | $244.0K |
| Pretax Income | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — |
| Net Income | — | $-26.6M | $-36.7M | $-30.5M | $-18.1M | $-10.0M | $-2.3M |
| Net Margin | — | — | — | -4,525.0% | -1,898.8% | — | — |
| EPS (Basic) | — | $-1.67 | $-2.83 | $-0.64 | $-0.60 | $-0.43 | $-0.14 |
| EPS (Diluted) | — | $-1.67 | $-2.83 | $-0.64 | $-0.60 | $-0.43 | — |
| Shares Outstanding (Basic) | 25.2M | 15.9M | 13.4M | 49.1M | 30.1M | 23.4M | 17.0M |
| Shares Outstanding (Diluted) | 25.2M | 15.9M | 13.4M | 49.1M | 30.1M | 23.4M | 17.0M |
| Dividends Per Share | — | — | — | — | — | — | — |